Chemical classes known as YKL-39 activators encompass a range of compounds that interact with biological pathways, resulting in the upregulation of the YKL-39 protein. These activators are not unified by a single chemical structure or class, but rather by their ability to engage with various cellular mechanisms that lead to an increase in the expression or activity of YKL-39. The pathways involved are diverse, including those that regulate inflammation, cell growth, tissue remodeling, and repair. For instance, certain inhibitors that target growth factor signaling pathways can induce changes in cellular behavior that necessitate the expression of proteins like YKL-39. These proteins may be upregulated as part of a complex response to the altered signaling dynamics, thereby contributing to the cellular adaptation to these changes.
Moreover, compounds that modulate the immune response through different receptors or signaling molecules also play a role in the regulation of proteins such as YKL-39. By influencing the intricate network of cytokines, growth factors, and other signaling entities, these activators can create a cellular environment that favors the expression of YKL-39. This is particularly evident in the context of inflammation and immune responses, where the balance of pro-inflammatory and anti-inflammatory signals can dictate the level of expression of specific proteins involved in these processes. Additionally, molecules that affect the synthesis of components of the extracellular matrix, which provides structural and biochemical support to surrounding cells, can also lead to an increased activity of YKL-39. Through these diverse methods of action, the compounds classified as YKL-39 activators contribute to the modulation of the protein's expression, reflecting the adaptive capacity of cellular systems to environmental and internal cues.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 inhibits TGF-beta signaling, which is involved in fibrosis and tissue remodeling, processes where YKL-39 could be upregulated. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib blocks PDGF receptors and could influence YKL-39 expression by altering the cellular response to tissue injury and repair. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits EGF receptors and could impact YKL-39 expression by modulating cell growth and repair mechanisms. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 inhibits FGF receptors, which may lead to changes in YKL-39 expression during processes like wound healing and angiogenesis. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone could modulate inflammation and fibrotic responses, potentially influencing YKL-39 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Tretinoin, an active metabolite of vitamin A, may alter YKL-39 expression through its role in cell differentiation and growth. | ||||||
4-Methylumbelliferone | 90-33-5 | sc-206910 sc-206910A sc-206910B sc-206910C sc-206910D | 25 g 100 g 250 g 1 kg 2.5 kg | $35.00 $56.00 $141.00 $431.00 $973.00 | 2 | |
4-Methylumbelliferone can stimulate the production of hyaluronic acid, which could affect YKL-39 in tissue remodeling. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Lysophosphatidic acid itself, acting through its receptors, could promote cell responses that result in YKL-39 expression changes. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate, through its anti-inflammatory action, might influence the levels of YKL-39 in immune-mediated processes. | ||||||